PriceTargets.com logo

Embecta - EMBC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.33
  • Forecasted Upside: 71.16%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$11.88 As of 04/25/2025 05:00 PM ET
▲ +0.13 (1.11%)

This chart shows the closing price for EMBC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$11.88Closing price on 04/26/25:
Get New Embecta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EMBC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EMBC

Analyst Price Target is $20.33
▲ +71.16% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Embecta in the last 3 months. The average price target is $20.33, with a high forecast of $26.00 and a low forecast of $15.00. The average price target represents a 71.16% upside from the last price of $11.88.

This chart shows the closing price for EMBC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$7.09$12$17$21$26Closing price on 04/26/25: $11.88High$26.00Average$20.33Low$15.00




Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Embecta. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/10/2025MizuhoInitiated CoverageNeutral$15.00
4/9/2025MizuhoUpgradeHold
12/2/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$13.00 ➝ $20.00
11/27/2024BTIG ResearchUpgradeNeutral ➝ Buy$26.00
7/15/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$13.00 ➝ $12.00
5/10/2024Morgan StanleyLower TargetUnderweight ➝ Underweight$16.00 ➝ $13.00
11/22/2023Morgan StanleyBoost TargetUnderweight ➝ Underweight$15.00 ➝ $16.00
10/20/2023Wolfe ResearchInitiated CoveragePeer Perform
10/18/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$16.00 ➝ $15.00
8/24/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$19.00 ➝ $16.00
7/18/2023Morgan StanleyLower TargetUnderweight$29.00 ➝ $19.00
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$28.00
12/21/2022Morgan StanleyLower TargetEqual Weight$33.00 ➝ $31.00
10/11/2022Morgan StanleyLower TargetEqual Weight$36.00 ➝ $33.00
9/8/2022BTIG ResearchInitiated CoverageNeutral
8/16/2022Morgan StanleyBoost TargetEqual Weight$33.00 ➝ $36.00
8/1/2022Morgan StanleyInitiated CoverageEqual Weight$33.00
6/21/2022Bank of AmericaInitiated CoverageUnderperform$25.00
(Data available from 4/27/2020 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2024
  • 9 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2024
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2025
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/26/2025
  • 11 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2025
  • 15 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2025

Current Sentiment

  • 15 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Embecta logo
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $11.88
Low: $11.54
High: $11.89

50 Day Range

MA: $12.70
Low: $10.91
High: $15.46

52 Week Range

Now: $11.88
Low: $10.00
High: $21.48

Volume

254,650 shs

Average Volume

456,111 shs

Market Capitalization

$690.63 million

P/E Ratio

11.88

Dividend Yield

5.34%

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Embecta?

The following equities research analysts have issued research reports on Embecta in the last year: BTIG Research, Mizuho, and Morgan Stanley.
View the latest analyst ratings for EMBC.

What is the current price target for Embecta?

0 Wall Street analysts have set twelve-month price targets for Embecta in the last year. Their average twelve-month price target is $20.33, suggesting a possible upside of 71.2%. BTIG Research has the highest price target set, predicting EMBC will reach $26.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $15.00 for Embecta in the next year.
View the latest price targets for EMBC.

What is the current consensus analyst rating for Embecta?

Embecta currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EMBC, but not buy more shares or sell existing shares.
View the latest ratings for EMBC.

What other companies compete with Embecta?

Other companies that are similar to Embecta include LeMaitre Vascular, LivaNova, Enovis, NovoCure and CONMED. Learn More about companies similar to Embecta.

How do I contact Embecta's investor relations team?

The company's listed phone number is 201-847-6880 and its investor relations email address is investor.relations@embecta.com. The official website for Embecta is www.embecta.com. Learn More about contacing Embecta investor relations.





Receive Embecta News & Ratings Daily
Sign up to receive the latest news and ratings for Embecta and its competitors with PriceTargets.com’s free daily newsletter.